Policy & Regulation
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
30 June 2020 - - Canadian therapeutic antibody discovery and development specialist ImmunoPrecise Antibodies Ltd (TSX Venture: IPA) (OTCQB: IPATF) (FSE: TQB2) has identified numerous lead candidate antibodies with highly-potent neutralizing activity in vitro, which are being manufactured for further testing and possible inclusion in the company's PolyTopeTM mAb Therapy to combat the COVID-19 pandemic, the company said.

On March 12th, 2020, ImmunoPrecise announced several preclinical programs currently being undertaken to assist in the efforts against SARS-CoV-2.

Today's announcement updates the company's progress on the development of a PolyTope mAb therapy designed to treat severely ill patients, as well as protect high-risk individuals such as those exposed to the virus, front-line workers, the elderly, and the immunocompromised.

ImmunoPrecise deployed several proprietary discovery platforms that leveraged the immune systems of humans, llama, rabbits and Ligand Pharmaceutical's (NASDAQ: LGND) OmniAbÒ genetically engineered rats producing human antibodies.

The neutralizing antibodies announced TODAY are the result of functional screenings from the top 300 lead antibodies analyzed from the human and llama campaigns.

The company has said that functional analysis of the remaining 1,300 lead antibodies from the rabbit and OmniAbÒ rat campaigns were performed independently, and they anticipate the release of the preliminary functional data screens from these additional programs in the near future.

The company's scientific approach has led to a diverse set of lead antibody candidates, and thus far has generated many potently neutralizing antibodies to multiple epitopes, supporting the company's aim of generating a therapeutic that retains efficacy, even as SARS-CoV-2 continues to evolve.

To further support the company's robust scientific approach, IPA is preparing to test these lead antibodies against additional, documented, mutated strains of the virus.

The company anticipates pre-clinical studies will begin summer 2020.

Jennifer Bath, Ph.D., chief executive officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.

The use of therapeutics for humans in clinical trials will require approval of the applicable government regulation agency, e.g. The company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.

ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients.